Related Experiment Videos
Inhaled nitric oxide in acute lung disease
1Department of Surgery, Brown University, Providence, RI, USA.
New Horizons (Baltimore, Md.)
|February 1, 1995
Summary
Inhaled nitric oxide (NO) selectively dilates pulmonary arteries, showing promise for acute lung injury. However, its effectiveness in ARDS requires further research and combination with anti-inflammatory treatments.
Area of Science:
- Pulmonary Medicine
- Critical Care
- Pharmacology
Background:
- Pulmonary artery hypertension is central to adult respiratory distress syndrome (ARDS).
- Inhaled nitric oxide (NO) selectively vasodilates pulmonary vasculature.
- Interest in inhaled NO as a treatment modality has surged.
Purpose of the Study:
- To evaluate the role of inhaled NO in treating acute lung disease and ARDS.
- To determine the efficacy of inhaled NO in various clinical and animal models.
- To identify patient subgroups most likely to benefit from inhaled NO therapy.
Main Methods:
- Review of existing literature on inhaled NO in acute lung disease and ARDS.
- Analysis of clinical observations and animal model studies.
- Identification of potential therapeutic benefits and limitations.
Main Results:
- Inhaled NO has shown potential for improving pulmonary function and reducing ventilatory support in some acute lung disease patients.
- Efficacy in animal models has been inconsistent.
- The precise role of inhaled NO in ARDS treatment remains uncertain.
Conclusions:
- Inhaled NO may serve as a useful adjunct in treating acute lung disease.
- Clinical utility in ARDS likely requires combination with anti-inflammatory therapies.
- Optimal benefit may be observed in patients with pressure-driven pulmonary edema and intrapulmonary shunt.